OvaRenew as a first-line therapy in impaired egg quality treatment

Información del proyecto

OvaRenew

Identificador del acuerdo de subvención: 743905

DOI

10.3030/743905

Proyecto cerrado

Fecha de la firma de la CE 15 Noviembre 2016

Fecha de inicio 1 Diciembre 2016

Fecha de finalización 31 Mayo 2017

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

POTENZA MEDICA D.O.O.
Slovenia

Periodic Reporting for period 1 - OvaRenew (OvaRenew as a first-line therapy in impaired egg quality treatment)

Período documentado: 2016-12-01 hasta 2017-05-31

Resumen del contexto y de los objetivos generales del proyecto

Our solution is tackling one of the deepest human needs-reproduction. The aim of OvaRenew project is to develop and globaly introduce OvaRenew, capsule for restoration of the impaired egg quality and quantity in woman with ovarian insufficiency as a first-line therapy. It will impact the low fertility rates, which result in increased population aging and have negative effects also on labour market, demography and economy of the developed world.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

On the basis of market (O.1) technological (O.2) bussiness model (O.3) economic (O.4) and organizational viability (O.5) plan for successful market penetration and plan for long-term profitability of OvaRenew was defined. The feasibility study confirmed likelihood of OvaRenew project being sucessful.

Market analysis confirms the huge potential of the ovarian infertility market of 27,1 billion € and our adressable market pharma triade region being 21,6 billion €, representing 80 % of global fertility market. Analysis of competitive solutions have shown that OvaRenew adresses all the needs and problems of the market in most effective and economical way and is therefore perfect candidate as a first-line approach in egg insufficiency. This is why we plan to capture 10 % of all ovarian insufficient woman in target markets. Our target is 640 mio €.

Estimated funds needed for a successful product launch are 1 mio €. It will be used mainly for manufacturing licence, clinical testing phase II/III, regulatory clearance, stability study, brand development and first market introduction. First sales is expected in 24 months after starting Phase 2 of the project. Break-even point will be reached near the end of the second year of commercialisation, presumably in 2021 with revenue planned to be 2,4 mio €. In 2023, ROI is planned to exceed 10, which will allow exit strategy for potentual investors as well as investment in the development of new products from the pipeline to ensure further growth.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

OvaRenew will enable women with impaired egg quality to produce their own child while drastically decreasing cost and invasiveness of the procedures on one and country health and other expenditures on the other hand. With our vision to become a globaly recognised producer of innovative fertility products, the OvaRenew technology goes directly in line with the strategy and innovation processes, which will greatly increase competitiveness of the company in the field of innovations, increase revenues and employment.

Execution plan for Phase 2 OvaRenew.